Month: April 2022

*** David Reardon, Luigi Naldini, Brad Loncar *** MILAN, Italy and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced it will hold a webinar entitled “Expert Perspectives: Immuno Gene & Cell Therapy for the Treatment of Solid Tumors” on Thursday, April 28, 2022 at 8:00 AM EDT / 2:00 PM CET. In this fireside chat, Genenta is delighted to bring together renowned neuro-oncologist David Reardon, MD (Harvard Medical School, Dana-Farber Cancer Institute) and Professor Luigi Naldini, MD, PhD (San Raffaele Telethon Institute for Gene Therapy), considered by many as the “father” of lentiviral gene therapy to discuss the potential application of immuno...

Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability findings from previous Phase 1/2 trial Enrollment in higher dose cohorts is ongoing with results expected in second half of 2022 Otonomy expects to initiate full dose-ranging Phase 2 efficacy trial by the end of 2022 Management will review results during a conference call today at 8:30 a.m. ETSAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive top-line results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss. The randomized, double-blind, placebo-controlled trial...

ZURICH, Switzerland, April 20, 2022 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces the completion of an Equity Subscription Agreement (“ESS”) with the institutional investor RiverFort Global Opportunities PCC Limited (“RiverFort”) for the next thirty six months. The agreement provides for up to USD$10.5 million to help finance the production of AptameX™ in Indonesia and the expansion of the business operations for the continued combating of the spread and impact of Covid-19 as well as for other contemporary diagnostics solutions beyond Covid-19. The facility was arranged by the FCA regulated intermediary RiverFort Global Capital Limited based in London. In addition to the ESS, RiverFort have entered into an unsecured loan...

— Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the three months ended March 31, 2022, after the closing of the U.S. equity markets on May 10, 2022. The Company will host a live conference call and webcast on May 11, 2022, at 8:00 a.m. ET. Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company’s website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows:Registration Link: http://apac.directeventreg.com/registration/event/5185688   Conference...

Highlights:Flowr has entered into a definitive agreement to sell Holigen to Akanda for aggregate consideration of approximately $35 million, including approximately $5.1 million of indebtedness being assumed by Akanda under the transaction, representing value of approximately $0.08 per share. The proposed Transaction also resulted in the immediate funding of operating expenses at Holigen. Flowr to preserve upside in E.U. business by receiving significant Akanda share consideration. The proposed Transaction significantly improves Flowr’s financial position by increasing cash by approximately $4.8 million and reducing indebtedness by approximately $5.1 million. In connection with the proposed Transaction, Akanda has agreed to subscribe for $1 million of common shares of Flowr, subject to the approval of the TSXV. The subscription ensures...

Los Angeles, CA., April 20, 2022 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce that Paul Mullen will participate in the inaugural Law-Tech Connect™ Workshop, produced by the esteemed P3 Tech Consulting LLC (“P3 Tech”). Co-located with AUVSI XPONENTIAL 2022, the event is taking place on April 25, 2022 at the Orange County Convention Center in Orlando, Florida. P3 Tech has partnered with the Association for Unmanned Vehicle Systems International (“AUVSI”) for XPONENTIAL 2022, the world’s premier event for unmanned systems and autonomy. XPONENTIAL features immersive workshops in partnership with specialized organizations to provide training, in-depth insights, and solutions on targeted...